Argentine researchers prove that two drugs are enough to treat HIV

Nicolás Maldonado

nmaldonado @ eldia .com

Although in the last decades, traditional treatment for people living with HIV has been based on three drugs, a research conducted by Fundación Huésped's scientific director, Dr. Pedro Cahn, shows that it could be reduced to two without losing efficiency. The study, based on another event in Argentina in 2009, but which now brings together patients from around the world, was presented this week at the World AIDS Conference held in Amsterdam.

According to the GEMINI study The new research involved more than 1,400 people living with HIV from Europe, the Americas, Africa and the Asia-Pacific region , who had not received any previous treatment. He specifically showed that a two-drug regimen (Dolutegravir and Lamivudine) has similar efficacy to that of a three-drug regimen, regardless of the viral load that patients initially present.

The survey in turn showed "generally consistent results for virus suppression in individuals with high viral load and in those with low viral load." None of the patients experienced Virologic failure and none of the treatment groups developed resistance, "according to a statement from the Foundation.

" In the past fifteen or twenty years, the standard of HIV treatment was d & # 39; 39, about one year.Three drug regimens.Now that we have more powerful drugs, the approach is aimed at improving tolerance and convenience.The GEMINI study has shown that we can get the right. Efficacy of the use of three drugs in a regime of two with the tolerability and interaction of a three-regimen, "says Dr. Cahn, for whom this new work" has the potential to 39, expand the paradigm of "

Although the results of GEMINI be very encouraging, the truth of his merit is to have tested on a large scale what the PADDLE study had already shown in 2009, a pilot project entirely carried out in Argentina by the team of researchers Fundación Huésped, which also sought to badyze the effectiveness of a dual treatment system.

PREVIOUS EVIDENCE

In turn, the PADDLE continued the line of GARDEL Study (designed, organized and led by Fundación Huésped), which showed that bi-therapy with Lamivudine schemas was all as effective therapy C is based on the two previous work that the ViiV laboratory has designed the multicenter international research that has just been presented in Amsterdam

As many know, the sponsor of the studies, the Foundation Huésped, is an Argentine organization of regional scope. that since 1989, works with the goal of guaranteeing treatment for HIV and the right to health. His work includes both the development of research and training and communication campaigns related to public health policies in our country

Research has shown consistent results in cases of high and low viral load